Why Pay More For Stryker When BSX Stock Is On Sale?

A medical device giant now costs more than its faster-growing rivals, forcing investors to decide if its premium price tag is buying durable quality or just yesterday’s story.

In the world of medical technology, investors pay 18.8 times operating income for Stryker, but only 14.3 times for rival Boston Scientific. This leaves investors with a pivotal question: why pay a premium for Stryker’s (SYK) lower growth when rival Boston Scientific—cheaper now after a complete reversal from last year—might be either a rare bargain or a warning sign for its business?

Stryker’s premium rests on scale and operational confidence.

With a market capitalization of about $106 billion, Stryker holds a clear size advantage over Boston Scientific ($63 billion) and Insulet ($9 billion). That scale comes with benefits, including a 21.7% operating margin—edging out Boston Scientific’s 21.0%—and a diverse portfolio of products.

Management’s recent commentary projects a powerful second half of the year, driven by what it calls an “elevated backlog” and “tremendous orders for our capital equipment.” This confidence is reflected in its updated full-year guidance, which now forecasts organic net sales growth in the range of 8.3% to 9.3%.

Stryker’s financial strength is also a core part of its appeal. The company has generated positive free cash flow consistently over the last three years and recently announced plans to “resume share repurchases,” citing its strong cash generation. This operational stability is paired with innovation, such as the recent full commercial launch of its Mako RPS handheld robotic system, designed to expand its reach in knee replacement procedures.

The key numbers side by side, today:

OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio

And the same comparison exactly a year ago, so you can see which way the mismatch has been moving:

OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio

Cheaper peers offer faster growth but bring their own questions.

By paying Stryker’s premium, an investor is explicitly passing on faster growth at a lower price. Boston Scientific (BSX) grew revenue at 13.5% over the last twelve months, well ahead of Stryker’s 8.5%. Yet its price to operating income multiple is just 14.3. The catch is that this lower multiple is new; a year ago it was a lofty 44.9. Following a 59.2% decline over the past 12 months, that steep drawdown raises the question of whether the patience is justified.The company’s recent guidance cut on both revenue and earnings per share suggests there are real operational issues for the market to weigh.

Insulet (PODD) presents a different challenge. It is also cheaper than Stryker, at 17.7 times operating income, but its growth is in another league entirely, with revenue expanding 29.4% over the last year.

While Insulet also trimmed its full-year revenue outlook, it contrasted with Boston Scientific by raising its forward guidance on adjusted EPS growth, signaling underlying margin momentum. For an investor focused on growth, Insulet presents an intriguing but volatile alternative: its valuation multiple has cratered from 59.1x to 17.7x amid a 60.9% 12-month share slide, and it carries a lower operating margin of 16.9%.

The choice turns on second-half execution.

Ultimately, the decision hinges on your confidence in Stryker’s ability to execute its ambitious second-half plan. To meet the midpoint of its guidance, Stryker needs to average roughly 11% organic growth across the back half of the year, an acceleration dependent on ramping up production. Management feels “very, very confident” it can deliver.

The tradeoff is clear: pay a premium for Stryker’s scale and management’s stated confidence in its operational recovery, or opt for a cheaper, faster-growing peer. The key thing to watch will be Stryker’s next earnings report. If the company demonstrates it is hitting that accelerated production and sales cadence, the premium may look justified. If it falters, the cheaper alternatives will look that much more attractive.

Prefer to run the numbers your own way?

You can line Stryker, Boston Scientific, and Insulet up directly on the Stryker peer comparison, weigh them on valuation, growth, margins, and returns, and swap in any other Health Care Equipment names you hold.

Paying the right price for growth is the whole game

This comparison is one instance of the only question that matters in stock picking: how much growth are you getting per dollar you pay? Most portfolios never ask it systematically, which is why most portfolios trail.

The Trefis High Quality (HQ) Portfolio is that question turned into a machine: roughly 30 businesses screened for real growth at defensible prices, held with discipline. It has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000. You just watched the test run on three stocks; own the version that runs on the whole market.